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This week’s special issue of Eurosurveillance highlights various 
aspects and challenges related to the prevention of influenza by 
vaccination. Influenza is among the infectious diseases with the 
highest incidence and associated serious morbidity and mortality 
that can be prevented by vaccination. In the article of the Vaccine 
European New Integrated Collaboration Effort (VENICE), investigators 
report details of vaccine coverage among different segments of 
the target population in the European Union (EU) and European 
Economic Area (EEA) Member States. Among elderly persons, only 
the Netherlands succeeded in reaching vaccine uptake levels above 
75%, the 2010 target of the World Health Organization (WHO); 
twelve countries reported 50% to 75% coverage, nine countries 
were even below the 2006 target of 50% and seven countries could 
not report any data. Importantly, vaccine uptake among clinical risk 
groups and health care workers was even lower. In a detailed report 
from France, F. Rance et al. reported that only 17% of asthmatic 
children were vaccinated against influenza. Furthermore, on behalf 
of the European Vaccine Manufacturers, M. Rodriquez de Azero 
et al. showed that the vaccine doses per capita only marginally 
increased from 17% to 20% in the years 2003 to 2006. So how 
can we be more successful in the prevention of influenza? 
In the United States (US), it has been estimated that on average 
51,000 persons die from influenza during epidemics each year [1]. 
Based mostly on figures from the US, most of the influenza burden is 
among persons with risk-elevating medical conditions such as chronic 
respiratory, cardio- or cerebrovascular or renal disease, diabetes and 
immunodeficiency, and among infants, older adults and residents of 
long-term health care settings [2]. Similar epidemiological studies 
in Europe could be of use to convince local politicians about the 
need to reduce the burden among these vulnerable groups. The 
Health Council of the Netherlands, for example, decided to lower 
the age threshold for vaccination from 65 to 60 years in 2007 
based on the large excess in the number of primary care visits, 
hospitalisations and mortality among the healthy aged 60 to 64 
years during epidemics [3]. Indeed, the lack of data on influenza 
burden at the more severe end of the clinical spectrum in many 
European countries probably contributes to the large variations in 
vaccine uptake reported to the VENICE investigators. 
The success of vaccination is largely determined by its impact 
on disease burden in the target group when applied in practice. 
Recently, the effects of influenza vaccination on the incidence of 
pneumonia and mortality from all causes among the elderly have been 
debated. In the US, the influenza-associated mortality among elderly 
persons has not declined over the last decades despite increase in 
vaccine uptake, whereas in the Netherlands a clear reduction in 
mortality seems to have taken place after the national influenza 
vaccination campaign [4,5]. These contrasting findings have led to 
much discussion mainly about the potential for confounding in non-
randomised observational studies, which may have had an impact 
on the validity of reported effect estimates so far. 
An important feature of randomisation is that it removes all 
kinds of biases; hence randomised controlled trials (RCTs) are 
considered the paradigm to study vaccine effects. Many RCTs have 
been conducted among healthy adults showing that vaccination 
prevented a considerable part of proven influenza infections [6]. 
Also, a landmark trial among elderly persons demonstrated a 50% 
reduction in influenza illness [7]. However, such trials with death 
as an outcome are unlikely to be carried out in Europe. Influenza 
vaccines are currently recommended for a wide variety of patients, 
and serious outcomes such as deaths due to infection are infrequent. 
Thus the design of an RCT would require very large representative 
study samples. Also the vaccines can only be effective when patients 
are actually exposed to the virus and the vaccine matches circulating 
strains neither of which can be predicted. Finally, placebo-controlled 
influenza vaccine trials in the elderly and most high-risk groups are 
usually considered unethical in Europe, since as the VENICE survey 
found vaccinating these persons is recommended in immunisation 
guidelines in most countries. 
Non-randomised case-control or cohort vaccine effectiveness 
studies are feasible alternatives to RCTs. They have the advantages 
of applicability in different patient populations, timeliness, reduction 
of costs, and increased feasibility. However, in observational studies 
the selection of patients for vaccination is influenced by their risk 
profile, which may lead to ‘confounding by indication’. Typically, 
the vaccinated group comprises patients with more severe disease 
or higher risk than the unvaccinated group. Crude, uncontrolled, 
estimates of the association between vaccination and outcome 
in such studies, therefore, lead to an underestimation of vaccine 
effectiveness. Conversely, if refusal of vaccination is typically 
associated with low functional health status, the unvaccinated group 
may comprise persons with a worse prognosis than the control group. 
This so-called ‘healthy user bias’ will lead to an overestimation of 
the true vaccine effectiveness. Both types of biases can be present 
in influenza vaccine studies and it is therefore a challenge to the 
investigator to prevent and adjust for the confounding in the design 
of data collection and analysis, and, if possible, to quantify its 
potential magnitude [8-10]. 
The report by M. Valenciano et al. provides the reader with a very 
complete overview of the observational studies that were conducted 
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in the EU Member States and the potential for confounding bias. 
The authors suggested that in designing studies aimed at measuring 
accurately and in a timely manner the vaccine effectiveness in 
Member States, based on an extensive literature review and expert 
meetings, case-control and cohort studies should be set up, and 
in the case-control study the main outcome should be laboratory-
confirmed influenza. In the same paper much attention has been 
given to measure as many potential confounding factors as possible. 
To quantify potential unmeasured bias it was suggested to also 
conduct cohort studies during pre- and post-influenza seasons. 
However, pre-influenza seasons are invalid reference seasons 
because influenza can still be present. Also, terminal patients 
may be included in cohorts evaluating the pre-influenza season, 
which can also induce selection bias such that vaccine effects are 
overestimated, because these patients may refrain from vaccination. 
These limitations notwithstanding and although more methods 
are available to quantify the potential impact of unmeasured 
confounding, the proposed studies are essential attempts to maintain 
confidence in the benefit of the vaccine programme.
Furthermore, country-specific data on influenza burden and 
European estimates of the effectiveness of vaccination are needed 
to estimate the cost-effectiveness of the vaccination programmes. 
Based on data from the Dutch PRISMA nested case-control study 
[11] and the abovementioned excess study [3], it was estimated that 
the vaccination programme in the Netherlands certainly resulted in 
saving money and concluded that it was cost-effective to vaccinate 
all adults aged between 60 and 64 years [12]. Consequently, 
the Dutch ministry of health decided to extend the vaccination 
programme to the lower age limit of 60 years. However, since the 
use of resources is different from country to country, such analysis 
should be initiated in each country or undertaken at an EU level to 
support the actual implementation of the vaccination programme.
Alarming reports of sudden cardiac failure after influenza 
vaccination in Israel [13] and the Netherlands [14] during the 2007 
influenza season had a negative impact on vaccine acceptance, even 
though national surveillance data indicated that these few fatal cases 
could be explained by chance alone and no causative relationship 
was found. Undoubtedly, more potent adjuvanted vaccines will 
replace current conventional vaccines in the next few years and 
many countries are currently considering stockpiling (pre)pandemic 
vaccines for use on a large scale in a pandemic. For these reasons, a 
carefully developed risk management plan is necessary to be able to 
prevent potential harm during mass vaccination campaigns [15].  
Finally, it needs to be acknowledged that the development 
of immunisation recommendations even when supported by, 
preferably local, evidence does not necessarily lead to acceptance 
of the vaccine by the public. Various factors determine the uptake 
of vaccination and educational programmes should be based on 
evidence from surveys that attempt to predict vaccine acceptance 
according to health behavioural and implementation models 
[16-19]. National commitment by government and professionals 
is crucial and this partly explains the successful performance of 
countries with better vaccination coverage. Such commitment is 
now needed at an EU level so that all countries can achieve such 
results. To conclude, collaborative action involving experts from the 
fields of public health, clinical epidemiology, psychology and health 
economy is needed to set up a European-wide infrastructure for 
studies on the epidemiology, (cost-)effectiveness, risk management 
and acceptance to further improve confidence and coverage in the 
influenza immunisation programmes. Reports published in this issue 
of Eurosurveillance provide useful guidance how to proceed.
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